Navigation Links
Lexiscan® (Regadenoson) Injection Study in Subjects With Asthma or Chronic Obstructive Pulmonary Disease (COPD) Presented as Late-Breaker at American Society of Nuclear Cardiology 2010
Date:9/25/2010

PHILADELPHIA, Sept. 25 /PRNewswire/ -- Today Astellas Pharma US, Inc. ("Astellas") announced results of a Phase IV study showing Lexiscan® (regadenoson) Injection was comparable to placebo in causing a >15% decrease in forced expiratory volume in one second (FEV1) in subjects with asthma or chronic obstructive pulmonary disease (COPD) who are likely candidates for myocardial perfusion imaging (MPI) studies(1). Results were presented during an oral presentation today at the 15th Annual Scientific Sessions of the American Society of Nuclear Cardiology (ASNC) in Philadelphia, Pennsylvania during a session highlighting late-breaker data.

Statistically, regadenoson was found to be not significantly different from placebo in causing a >15% decrease in FEV1 in patients with asthma (p = 0.1451) or COPD (p = 0.5790). Additionally, the change in FEV1 was not affected by baseline disease severity for either the asthma or the COPD subject groups.

Researchers evaluated 999 adult male and female patients (532 asthma and 467 COPD) 18 years of age and older in a multicenter, randomized, double-blind, placebo-controlled study to determine the safety and tolerability of regadenoson in subjects with asthma (FEV1 >60% predicted) or stable COPD (FEV1/FVC <0.70). The subjects had a diagnosis of CAD or risk factors for CAD as determined by a current medical diagnosis of at least two of the following conditions: Type 2 diabetes, hypertension, hypercholesterolemia, current or history of cigarette smoking (minimum 10 pack-years exposure) or obesity Body Mass Index (BMI > 30). A 2:1 randomization to receive a single 10-second IV injection of Lexiscan 0.4 mg (in 5 mL) or placebo was used.

Treatment-emergent adverse events were similar in frequency and severity to those observed in previous studies of regadenoson. Two regadenoson subjects in the COPD group received aminophylline for treatment of adverse events.

About Myocardial Perfus
'/>"/>

SOURCE Astellas Pharma US, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
2. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
3. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
4. Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
5. New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma
6. Isolagen Inc. Completes Injections of Isolagen Therapy(TM) in Phase III Wrinkle and Phase II Full Face Studies
7. FDA Advisory Committee Supports Efficacy and Safety of Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
8. Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkins Lymphoma
9. Inclusion of Six-Year Overall Survival Data in the Eloxatin(R) (oxaliplatin injection) Prescribing Information Granted FDA Priority Review
10. Circulation Publishes Data Showing KYNAPID(TM) (Vernakalant Hydrochloride) Injection Rapidly Converted Short-Duration Atrial Fibrillation to Sinus Rhythm
11. CorMatrix(R) Announces Intramyocardial Injection of Emulsified ECM Technology(TM) Demonstrates Enhanced Angiogenesis and Improved Cardiac Function in a Preclinical Model
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... TARRYTOWN, N.Y. , May 21, 2013 /PRNewswire/ ... Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the ... positive Phase 2a study results of dupilumab (SAR231893/REGN668) in ... monoclonal antibody targeting the alpha subunit of the interleukin ... IL-4 and IL-13, drivers of Th2 (Type 2 helper ...
(Date:5/21/2013)... 2013 Abaxis, Inc. (NasdaqGS: ABAX), a medical ... that Martin Mulroy , chief commercial ... & Veterinary Conference on Wednesday, May 29, 2013 at ... Le Parker Meridien Hotel in New York ... Abaxis develops, manufactures, markets and sells portable blood analysis ...
(Date:5/21/2013)... YORK , May 21, 2013 /PRNewswire/ ... research report is available in its catalogue: ... Regulatory and Reimbursement Scenario for Medical Devices ... http://www.reportlinker.com/p01188015/Changing-Regulatory-and-Reimbursement-Scenario-for-Medical-Devices-in-the-US-Market.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Imaging   Changing ... in the US Market   ...
Breaking Medicine Technology:Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 2Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 3Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 4Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 5Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 6Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 7Abaxis, Inc. to Present at the Stifel Annual Dental & Veterinary Conference 2Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 2Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 3Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 4
... 9, 2011 /PRNewswire-Asia/ -- Vaccines made in China ... agencies to developing countries, after recognition from the ... and Drug Administration (SFDA) has complied with international ... regulatory system is a precondition that could lead ...
... Watson Pharmaceuticals, Inc. (NYSE: WPI ... Court for the District of Massachusetts has granted ... Inc. for a temporary restraining order (TRO) preventing ... selling Amphastar,s Enoxaparin Sodium Injection product, a generic ...
Cached Medicine Technology:VacChina 2011 International Conference Meets in Shanghai This November 2Watson Confirms District Court Order Concerning Generic Version of LOVENOX(R) 2Watson Confirms District Court Order Concerning Generic Version of LOVENOX(R) 3
(Date:5/21/2013)... 2013 Octo Consulting Group, an ... consulting solutions to the Federal marketplace, has named ... In the newly created role, Denny will be ... the firm’s business development function to include business ... and leading strategies to achieve the firm’s strategic ...
(Date:5/21/2013)... HealthDay Reporter , , TUESDAY, May 21 (HealthDay ... steroid therapy for patients having severe bouts of chronic ... Five days of glucocorticoid treatment with prednisone to treat ... days, but with fewer chances for adverse side effects, ... shorter period of treatment was not less effective than ...
(Date:5/21/2013)... HealthDay Reporter , , TUESDAY, May 21 (HealthDay News) ... of sleep apnea in children, and while removing them ... kids, it did help them with sleep, behavior and ... apnea is a condition that causes abnormal pauses in ... in sleep with the surgery, and those improvements were ...
(Date:5/21/2013)... at high risk for developing lung cancer shows that ... helping clinicians spot tiny lung nodules which, in a ... of the disease. LDCT uses less than a quarter ... Results of the study will be presented at the ... leading cause of cancer-related death and has a poor ...
(Date:5/21/2013)... Mexican young adults may have a genetic predisposition for ... a study at the Universidad Autnoma de San Luis ... from both parents were already 15 pounds heavier and ... hadn,t. They also had slightly higher fasting glucose levels," ... food science and human nutrition. , In the study, ...
Breaking Medicine News(10 mins):Health News:Octo Consulting Group Appoints Tracy Denny as Vice President of Business Development 2Health News:COPD Patients May Do Fine With Shorter Course of Steroids 2Health News:COPD Patients May Do Fine With Shorter Course of Steroids 3Health News:Removing Tonsils Helps Kids With Sleep Apnea, Study Finds 2Health News:Removing Tonsils Helps Kids With Sleep Apnea, Study Finds 3Health News:Low radiation scans help identify cancer in earliest stages 2Health News:Low radiation scans help identify cancer in earliest stages 3Health News:Genetic risk for obesity found in many Mexican young adults 2
... Treatment of heart patients no better after performance data released ... -- One might assume that public report cards ranking their ... study finds that isn,t the case. , Researchers found ... better job of treating heart patients after report cards were ...
... , ... November 16, 2009. , ... November 18, 2009 -- Ziosoft®, Inc. http://www.ziosoftinc.com -- a leader in advanced visualization ... vice president, sales and marketing, effective November 16., , , , ,Most recently, Royea served ...
... ... and Security Suite to deliver end-to-end endpoint management solution capabilities on a single ... ... 2009 -- Lumension , a global leader in endpoint management and security, ...
... Physicians for Social Responsibility today released a groundbreaking ... look at the devastating impacts of coal on the human body. ... organ systems of the human body, the report concludes that coal ... the U.S. and is responsible for increasing the incidence of major ...
... , MINEOLA, N.Y., Nov. 18 The United ... for when a woman should be getting a mammography. ... has made an official statement regarding her research and ... , Yesterday, The United States Preventive Services Task ...
... , BRIGHTON, Mass., Nov. 18 Sleep Health Centers ... US, is proud to announce the formation of SleepPartners ( ... accredited sleep centers with board-certified sleep specialists and a focus ... sleep programs combined with their geographic reach extends high quality ...
Cached Medicine News:Health News:Study Shows Hospital Report Cards Unlikely to Spur Improvement 2Health News:Ziosoft Announces the Appointment of Rob Royea, Vice President, Sales and Marketing 2Health News:Lumension Endpoint Management Platform Strategy to Reduce Complexity, Enhance Security & Compliance, and Expand Visibility across IT Operations and Security Functions 2Health News:Lumension Endpoint Management Platform Strategy to Reduce Complexity, Enhance Security & Compliance, and Expand Visibility across IT Operations and Security Functions 3Health News:Lumension Endpoint Management Platform Strategy to Reduce Complexity, Enhance Security & Compliance, and Expand Visibility across IT Operations and Security Functions 4Health News:Lumension Endpoint Management Platform Strategy to Reduce Complexity, Enhance Security & Compliance, and Expand Visibility across IT Operations and Security Functions 5Health News:Lumension Endpoint Management Platform Strategy to Reduce Complexity, Enhance Security & Compliance, and Expand Visibility across IT Operations and Security Functions 6Health News:Lumension Endpoint Management Platform Strategy to Reduce Complexity, Enhance Security & Compliance, and Expand Visibility across IT Operations and Security Functions 7Health News:Lumension Endpoint Management Platform Strategy to Reduce Complexity, Enhance Security & Compliance, and Expand Visibility across IT Operations and Security Functions 8Health News:Coal Pollution Damages Human Health at Every Stage of Coal Life Cycle, Reports Physicians for Social Responsibility 2Health News:Coal Pollution Damages Human Health at Every Stage of Coal Life Cycle, Reports Physicians for Social Responsibility 3Health News:Coal Pollution Damages Human Health at Every Stage of Coal Life Cycle, Reports Physicians for Social Responsibility 4Health News:Coal Pollution Damages Human Health at Every Stage of Coal Life Cycle, Reports Physicians for Social Responsibility 5Health News:Maurer Foundation for Breast Health Education Statement on USPSTF Guidelines for Mammography 2Health News:Sleep HealthCenters Launches SleepPartners(TM) Network 2
... An Antiseptic Antibacterial that does ... than 30 seconds, destroys over ... used for cleansing of minor ... for disinfection of personal utensils ...
... Bactericide, Microbicide for professional degerming, pre-op ... skin disinfectants combining quaternary and substituted ... blend of emollients and surfactants. Unprecedented ... organisms tested in 30 seconds. Techni-Care ...
Aplicare's disposable 1-ounce pouches are designed for individual application and are ideal for reducing waste. They are used in nursing homes, home healthcare settings, blood banks, laboratories, em...
... solution is for broad-spectrum germicidal ... is labeled for single use ... contamination. The controlled spray mist ... the final step of the ...
Medicine Products: